In the largest clinical trial that tested Wegovy before its FDA approval, people taking the highest dose (2.4 milligrams) lost, on average, more than 12% of their body weight over 17 months
Answer : The driving factors of the GLP-1 analogues market are the rising prevalence of diabetes and obesity, driving demand for effective treatment options
Symptoms including enlarged organs, blood abnormalities, and bone disease
Strength Training Needs to Be Part of the Plan If you are using a GLP-1 and want better long-term results, strength training should be a priority
Microdosing Retatrutide Explore split-dose protocols, benefits, risks, and pharmacokinetic modeling
The New England Journal of Medicine, 384 (11), 989-1002